The Poultry Healthcare Division delivered 18 per cent growth in Q2 FY26 and 10 per cent growth in H1 FY26, driven by volume gains and sustained demand for core vaccines.

Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 14.33 crore for the Q2 FY25-26, rise of 71 per cent as compared to the net profit of Rs. 8.39 crore reported in the second quarter of FY 2024-25. Revenue from operations of the company for the Q2FY26 was reported at Rs.70.97 crore. EBITDA for Q2FY26 was reported at Rs. 23.60 crore (EBITDA margin 33 per cent) as against EBITDA of Rs. 21.96 crore (EBITDA margin 26 per cent) in Q2FY25. EPS for Q2 FY26 was Rs. 16.85 per share. Consolidated results include operations of subsidiaries from Nepal and Tanzania.

Net Profit for H1 FY26 was reported at Rs. 31.63 crore, up 99 per cent Y-o-Y from Rs. 15.88 crore in the corresponding period last year. EBITDA for H1FY26 was reported at Rs. 49.78 crore (EBITDA margin 32 per cent) as against EBITDA of Rs. 41.69 crore (EBITDA margin 25 per cent) in Q2FY25. For H1 FY26, company reported revenue of Rs. 155.07 crore. The company maintained strong operational discipline, through controlled overheads, process standardisation, and efficient manpower deployment. The focus remains on margin protection and cost optimisation, while positioning for an expected recovery in volumes during the second half of the year.

Hester Africa reported a net profit of Rs 4.82 crore in Q2 FY26 and Rs 10.32 crore in H1 FY26, on toplines of Rs 5.99 crore and Rs 23.22 crore, respectively. Profit growth was supported by improved operational discipline and favourable foreign exchange movements. However, order flows across certain geographies remain subdued due to delays in project approvals and political transitions. The company expects market conditions to stabilise and institutional demand to recover over the next few quarters.

Way Forward

· The company has internally taken a decision to strengthen business fundamentals by reducing dependence on tender-based revenues to build a more balanced and resilient portfolio. This is in line with our objective to reduce dependency on any territory or any products.

· Efforts continue to deepen presence across commercial, private, and export markets, supported by operational discipline and process standardisation.

· With H9N2 now receiving market authorisation, several export opportunities are expected to open up, creating new markets and partnerships.

· H9N2 represents a key growth driver for Hester, enhancing its ability to expand into new regions and strengthen its leadership in the poultry health segment.

· Going forward, the company will continue to drive innovation, margin stability, and sustainable growth through product diversification and geographic expansion.